[Form 4] DarioHealth Corp. Insider Trading Activity

Rhea-AI Filing Summary

DarioHealth Corp. director Dennis Matheis reported a non‑derivative acquisition of company stock. On 09/11/2025 Mr. Matheis received a restricted share award of 20,000 shares at a reported price of $0. The award is scheduled to vest on the last day of the second anniversary after the grant date. Following the reported transaction, Mr. Matheis beneficially owned 27,631 shares, an amount that reflects a 20‑for‑1 reverse stock split effected on August 28, 2025. The Form 4 was signed on 09/15/2025.

Positive

• Director alignment: Awarded 20,000 restricted shares that vest over two years, aligning the director's interests with shareholders
• Transparent disclosure: Form 4 filed and signed on 09/15/2025, documenting the grant and post‑split ownership

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Director received restricted equity; vesting schedule aligns incentives without immediate cash outlay.

The reported transaction shows a typical restricted share award to a director rather than a sale or open‑market purchase. The award price is $0, indicating a grant rather than a purchase, and it vests on the last day of the two‑year anniversary period, creating a time‑based retention incentive. The post‑transaction beneficial ownership figure incorporates a 20‑for‑1 reverse split, which is a corporate action that alters share counts but not ownership percentage absent other changes. This filing is routine corporate governance disclosure and does not by itself provide information on company performance or valuation.

Securities Analyst

TL;DR: Insider award increases director alignment but is immaterial alone for valuation.

The Form 4 reports a non‑cash grant of 20,000 restricted shares to a director on 09/11/2025 with vesting after two years. Such grants are commonly used to align directors with shareholder interests. The filing notes the 20‑for‑1 reverse split on August 28, 2025, which explains the reported 27,631 shares beneficially owned after the transaction. The disclosure is specific to ownership change and contains no financial performance metrics; its investor impact is likely minimal without additional context.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Matheis Dennis

(Last) (First) (Middle)

322 W 57TH STREET, #33B

(Street)

NEW YORK NY 10019

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DarioHealth Corp. [ DRIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2025(1)		A		20,000	A	$0	27,631(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted share award shall vest on the last day of the second-year anniversary after the grant date.

2. The number of shares beneficially owned reflects the 20-for-1 reverse stock split effected on August 28, 2025.

	/s/ Dennis Matheis	09/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Dennis Matheis report on the Form 4 for DRIO?

He reported a restricted share award of 20,000 shares on 09/11/2025 and beneficial ownership of 27,631 shares after a 20‑for‑1 reverse split.

When do the restricted shares awarded to Dennis Matheis vest?

The restricted share award will vest on the last day of the second‑year anniversary after the grant date.

What price was reported for the awarded shares on the Form 4?

The award was reported with a price of $0, indicating a grant rather than a purchase.

Does the Form 4 mention any derivative transactions for DRIO by Dennis Matheis?

No. The filing reports only a non‑derivative restricted share award and contains no derivative transactions.

Why does the Form 4 list 27,631 shares after the transaction?

The filing states that the 20‑for‑1 reverse stock split on August 28, 2025 is reflected in the beneficial ownership number.